We are pleased to announce the publication of the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Read the news release:
kdigo.co/2025-ADPKD-Guidelin…
This first-ever KDIGO guideline focused on a rare kidney disease provides practical tools for healthcare providers and patients to improve diagnosis, care, and treatment, addressing challenges in managing this inherited condition.
"This comprehensive guideline reflects the significant progress in ADPKD research over the last decade, from genetic insights to advanced therapies," said Guideline Co-Chair Vicente E. Torres, MD. "By addressing the complexities of diagnosis, treatment, and management, we hope this guideline will standardize care, enhance clinical practices, and help reduce the global burden of ADPKD. Our goal is that this resource will not only empower clinical decision-making but also inspire hope for patients and their families, demonstrating that meaningful progress is achievable for this challenging disease."
"The publication of this guideline represents a pivotal step forward in the care of ADPKD and people with rare genetic disorders worldwide," said Guideline Co-Chair Olivier Devuyst, MD. "It is the result of an extraordinary global collaboration among experts, researchers, and patient advocates, bringing together the best available evidence to guide care across diverse settings. This guideline is not just important for individuals with ADPKD. It also serves as a crucial template for the development of guidance for other rare genetic conditions. By providing a roadmap for consistent, evidence-based care, it addresses critical knowledge and practice gaps worldwide, offering a model for improving the lives of those with rare diseases globally."
Download the KDIGO ADPKD Guideline, Executive Summary, and Data Supplement on the guideline website:
kdigo.co/ADPKD
Read the guideline in
@Kidney_Int:
kdigo.co/ADPKD-Guideline-KI
#ADPKD